We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cancer Drugs Face Coverage Challenges in UK, PhRMA Says

Cancer Drugs Face Coverage Challenges in UK, PhRMA Says

July 21, 2014

Drugmakers are facing tougher hurdles in getting new cancer drugs covered in the UK, according to a U.S industry trade group. But some observers and UK government officials counter that the majority of these expensive treatments are still being widely reimbursed, even if they come with some restrictions.

In a recent report, PhRMA said the rate at which the UK’s National Institute for Health and Care Excellence (NICE) rejects cancer medicines has been increasing in recent years.

Last year, for example, the agency rejected all six cancer medicines it reviewed, according to the July 11 PhRMA-sponsored report, written by healthcare information and data analytics firm Context Matters. In 2008, by contrast, NICE recommended rejecting only 33 percent of its oncology drug appraisals, and recommended coverage with restriction in 50 percent of the cases.

Furthermore, the report says, from 2007 through last year, NICE gave 56 percent of the cancer drugs it reviewed a non-coverage recommendation, compared with only 16 percent of non-cancer products.

The report cites NICE’s September 2013 rejection of Pfizer’s lung cancer drug Xalkori (crizotinib) as an example of how the agency’s appraisals “conflict with patient needs and continued medical progress.” Xalkori, which costs roughly $115,000 per year, provides a median gain of 5.1 months in progression-free survival compared with another drug, docetaxel.

A NICE spokesman disputed the study’s conclusions. NICE is prepared to accept higher premiums for cancer treatments than it usually accepts for non-cancer drugs, he said.

“And even when NICE recommends against the routine use of a cancer drug, the NHS in England makes it available anyway,” he said referring to a fund called the Cancer Drugs Fund, which was created in 2011 specifically to pay for cancer treatments in England that either haven’t been reviewed yet or didn’t pass NICE’s cost-effectiveness test.

PhRMA contends the need to establish the fund in the first place demonstrates the restrictiveness of NICE decisions. Many patient groups are fearful that, if the fund does not continue to receive funding, “access to cancer medicines will revert to being the worst in Europe, with more than 16,000 patients a year denied help,” the report says.

Joshua Cohen, Ph.D., a researcher at the Tufts Center for the Study of Drug Development, says that NICE is more flexible than the Context Matters report indicates. Overall, he said, people looking at recent trends in NICE’s reimbursement of cancer drugs shouldn’t draw too negative a conclusion.

“You have to look at it from a relative perspective,” he said. Even though NICE may be covering less than it used to, over the long run, Cohen said, “in the UK, most cancer drugs get approved for reimbursement…and 85 to 90 percent [of drugs] get past the NICE hurdles.” — Lena Freund

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Commercial Operations
  • Related Events

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing